| Gruenenthal GmbH Patent applications |
| Patent application number | Title | Published |
|---|
| 20130123324 | Crystalline (1r, 4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1- ,1'-pyrano[3,4,b]indol]-4-amine - Crystalline forms of (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these crystalline modifications, the use of these modifications as well as a process for the enrichment of such crystalline modifications. | 05-16-2013 |
| 20130116334 | Treatment of Irritable Bowel Syndrome - A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol. | 05-09-2013 |
| 20130085184 | Intrathecal or Epidural Administration of 3-[(1S,2S)-3-(Dimethylamino)-1-Ethyl-2-Methylpropyl]Phenol - The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes. | 04-04-2013 |
| 20130079377 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands - The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 03-28-2013 |
| 20130079320 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands - The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 03-28-2013 |
| 20130060065 | Process for the Dehydration of Substituted 4-Dimethylamino-2-aryl-butan-2-ol Compounds and Process for the Preparation of Substituted Dimethyl-(3-aryl-butyl)- Amine Compounds by Heterogeneous Catalysis - Process for the preparation of substituted dimethyl-(3-aryl-butyl)-amine compounds. The process comprises dehydration by heterogeneous catalysis of substituted 4-dimethylamino-2-aryl-butan-2-ol compounds, to form substituted dimethyl-(3-aryl-but-3-enyl)-amine intermediates, which are then converted by hydrogenation with hydrogen to substituted dimethyl-(3-aryl-butyl)-amine compounds. | 03-07-2013 |
| 20130029995 | Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1). | 01-31-2013 |
| 20130029962 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders. | 01-31-2013 |
| 20130029961 | Substituted Heterocyclic Aza Compounds - Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders. | 01-31-2013 |
| 20130022670 | Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration - An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives. | 01-24-2013 |
| 20130012563 | CRYSTALLINE (1R,4R)-6'-FLUORO-N,N-DIMETHYL-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO[CYCLOHEXA- NE-1,1'-PYRANO[3,4,B]INDOL]-4-AMINE - Crystalline forms of (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these crystalline modifications, the use of these modifications as well as a process for the enrichment of such crystalline modifications. | 01-10-2013 |
| 20120309841 | Method of Inhibiting Chronification of Pain - The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine. | 12-06-2012 |
| 20120309840 | Treatment of Pain Associated with Trigeminal Neuralgia - The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia. | 12-06-2012 |
| 20120302643 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 11-29-2012 |
| 20120302602 | Vanilloid Receptor Ligand Compounds, Pharmaceutical Compositions Containing Them, a Method of Producing Them and the Use Thereof to Treat Pain and Various Other Conditions - Compounds corresponding to formula I: | 11-29-2012 |
| 20120277319 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 11-01-2012 |
| 20120258946 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions. | 10-11-2012 |
| 20120251637 | Abuse-proofed dosage form - The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 10-04-2012 |
| 20120225951 | Parenteral Administration of Tapentadol - An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4. | 09-06-2012 |
| 20120225950 | Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol - A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof. | 09-06-2012 |
| 20120178809 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof - Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate compounds corresponding to formula I | 07-12-2012 |
| 20120149914 | Method for Synthesizing Substituted Aminocyclohexanone Compounds - A method of synthesizing a substituted aminocyclohexanone compound comprising reacting a compound of formula (II) | 06-14-2012 |
| 20120115903 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted heteroaromatic carboxamide and urea compounds corresponding to formula (i) | 05-10-2012 |
| 20120115893 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Substituted bicyclic carboxamide and urea compounds corresponding to formula (I) | 05-10-2012 |
| 20120107250 | ABUSE-PROOFED DOSAGE FORM - An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 05-03-2012 |
| 20120071461 | Substituted Benzamide Compounds - Substituted benzamide compounds corresponding to formula (I) | 03-22-2012 |
| 20120058999 | Substituted Tetrahydropyrrolopyrazine Compounds - Tetrahydropyrrolopyrazine compounds, methods for their preparation, pharmaceutical compositions containing such compounds, and a method of using such compounds for the treatment of pain and other conditions mediated at least partially by Bradykinin 1 receptors (B1R). | 03-08-2012 |
| 20120046301 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor - Substituted cyclic carboxamide and urea compounds, a process for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment and/or inhibition of pain and other conditions mediated by the vanilloid receptor 1. | 02-23-2012 |
| 20120041071 | TAPENTADOL FOR TREATING PAIN DUE TO OSTEOARTHRITIS - The use of tapentadol for treating pain due to osteoarthritis. | 02-16-2012 |
| 20120039963 | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation - A pharmaceutical dosage form for controlled release of the active substance 3-(2-dimethylaminomethylcyclohexyl)-phenol, preferably (1R,2R)-3-(2-dimethylaminomethylcyclohexyl)-phenol, or a pharmaceutically acceptable salt thereof, which dosage form (i) in vivo produces a peak plasma level of the active substance after 2 to 10 hours, and/or (ii) in vitro releases 3.0 to 37 percent by weight of the active substance originally contained in the dosage form after one-half hour, 5.0 to 56 percent by weight after one hour, 10 to 77 percent by weight after two hours, 15 to 88 percent by weight after 3 hours, at least 30 percent by weight after six hours, at least 50 percent by weight after 12 hours, at least 70 percent by weight after 18 hours, and at least 80 percent by weight after 24 hours when measured according to the European pharmacopoeia using a blade mixer in preferably 900 ml of a buffer solution at a pH value of 6.9, a temperature of 37° C., and 75 rpm. | 02-16-2012 |
| 20120034304 | Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol - A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours. | 02-09-2012 |
| 20120034297 | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3- ,4,b]indol]-4-amine - A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6′-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof. | 02-09-2012 |
| 20120034171 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 02-09-2012 |
| 20120029006 | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine Compounds - Cis-tetrahydro-spiro(cyclohexane-1,1′-pyrido[3,4-b]indole)-4-amine compounds which act on the nociceptin/ORL-1 receptor system as well as on the μ-opioid receptor system and which are distinguished in particular by selective effectiveness in the treatment of chronic pain, such as inflammatory pain, visceral pain, tumour pain, and neuropathic pain, without at the same time developing pronounced effectiveness against acute, nociceptive pain. | 02-02-2012 |
| 20120022294 | Axomadol or a Metabolite Thereof for Use in the Treatment of Irritable Bowel Syndrome - The invention relates to axomadol or a metabolite thereof for use in the treatment of irritable bowel syndrome. | 01-26-2012 |
| 20120022117 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol - A salt or cocrystal of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (component a) and at least one acid component (b1) or at least one acid component (b2), wherein the salt or cocrystal of component (a) and component (b2) is present in crystalline and/or amorphous form, a pharmaceutical composition comprising said salt or cocrystal, and a method of treating pain in a subject in need thereof by administering an effective amount of said salt or cocrystal. | 01-26-2012 |
| 20120016023 | Combination of Selected Opioids with Muscarine Antagonists for Treating Urinary Incontinence - Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided. | 01-19-2012 |
| 20120004317 | Tapentadol for use in the treatment of irritable bowel syndrome - The invention relates to tapentadol for use in the treatment of Irritable Bowel Syndrome | 01-05-2012 |
| 20110319440 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds - Spirocyclic cyclohexane compounds corresponding to formula I | 12-29-2011 |
| 20110306793 | Process for Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds - A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds. | 12-15-2011 |
| 20110306674 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 12-15-2011 |
| 20110306673 | CRYSTALLINE FORMS OF (1RS,2RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DI- OL HYDROCHLORIDE - This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1. | 12-15-2011 |
| 20110301156 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 12-08-2011 |
| 20110295038 | Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds - A process for the preparation of substituted 1-aminomethyl-2-phenyl-cyclohexane compounds. | 12-01-2011 |
| 20110294898 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 12-01-2011 |
| 20110281855 | NOVEL AND POTENT TAPENTADOL DOSAGE FORMS - The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol. The present invention further provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol. | 11-17-2011 |
| 20110263699 | 1-Phenyl-2-DimethylaminomethylCyclohexane Compounds and Therapies for Depressive Symptoms, Pain and Incontinence - Metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing a medicament used for treating depression, and related methods of treating depression, pain and urinary incontinence. | 10-27-2011 |
| 20110257048 | Reactor Array for Producing and Analyzing Products - The present invention relates to a reactor array for producing and/or analysing products, comprising a plurality of vessels in which products can be produced on a preparative or analytical scale. | 10-20-2011 |
| 20110251287 | HCI POLYMORPHS OF 3-((2-(DIMETHYLAMINO)METHYL (CYCLOHEX-1-YL))PHENOL - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 10-13-2011 |
| 20110251286 | Crystalline salts and/or co-crystals of O-desmethyltramadol - Salts and/or co-crystals of (+)-3-[2-(dimethylamino)-methyl-1-hydroxycyclohexyl]-phenol or of (−)-3-[2-(dimethylamino)methyl-1-hydroxy-cyclohexyl]phenol, present in crystalline form, with cinnamic acid, C | 10-13-2011 |
| 20110245106 | Sample Carrier and Method for Achieving Comparable Analytical Results By Aligning Test Substances on a Uniform Plane - A sample carrier such as a multi-well platform with one or more recesses, in each of which a substance to be analyzed is disposed, and an analysis method in which one or more substances, each of which is located in a recess of the sample carrier, are aligned on a uniform plane relative to the surface of the sample carrier before being analyzed. | 10-06-2011 |
| 20110224172 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods - Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds. | 09-15-2011 |
| 20110184020 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 07-28-2011 |
| 20110060053 | Crystalline Modifications of 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol - Crystalline modifications of (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol and mixtures thereof, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of (1R,3R,6R)- or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol. | 03-10-2011 |
| 20110053970 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency. | 03-03-2011 |
| 20110053914 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic - A pharmaceutical combination comprising: | 03-03-2011 |
| 20110046230 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof - Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate compounds corresponding to formula I | 02-24-2011 |
| 20110015161 | PHARMACEUTICAL CONTAINING A HOROMONE COMBINATION HAVING A CONTRACEPTIVE EFFECR AND AN INSULIN SENSITIZER - The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-β-OH-chlormadinone acetate, 3-α-OH-chlormadinone acetate, 3-α-acetoxy-chlormadinone acetate and 3-β-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception. | 01-20-2011 |
| 20110009382 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles - Substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, pharmaceutical compostions containing these compounds and the use of these compounds for treating or inhibiting disorders or disease states mediated at least in part by bradykinin receptor 1 (BR1). | 01-13-2011 |
| 20110003795 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands - The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 01-06-2011 |
| 20100331425 | Tapentadol for Treating Pain due to Osteoarthritis - The use of tapentadol for treating pain due to osteoarthritis. | 12-30-2010 |
| 20100331424 | Use of Axomadol for Treatment of Arthrosis Pain - The use of axomadol for the treatment of pain in arthrosis. | 12-30-2010 |
| 20100331381 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 12-30-2010 |
| 20100324009 | Substituted Sulfonamide Compounds - Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states. | 12-23-2010 |
| 20100317644 | Substituted Sulfonamide Compounds - Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states. | 12-16-2010 |
| 20100316615 | Antisense Oligonucleotides Against VR1 - Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances. | 12-16-2010 |
| 20100311842 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain - Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy. | 12-09-2010 |
| 20100280129 | Method of Treating Pain Caused by Inflammation - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amoung of a (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound or a physiologally acceptable salt thereof, such as the hydrochloride or citrate salt. | 11-04-2010 |
| 20100280128 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain - The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain. | 11-04-2010 |
| 20100280126 | Method of Inhibiting Inflammatory Pain - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt. | 11-04-2010 |
| 20100280017 | Combination of Selected Analgesics and Cox-II Inhibitors - Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain. | 11-04-2010 |
| 20100249225 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders - Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant. | 09-30-2010 |
| 20100249095 | Substituted Spiro-amide Compounds - Substituted spiro-amide compounds corresponding to formula I | 09-30-2010 |
| 20100240897 | Spirocyclic Cyclohexane Compounds - Spirocyclic cyclohexane compounds corresponding to formula I | 09-23-2010 |
| 20100234340 | Substituted Spiroamide Compounds - Substituted spiroamide compounds corresponding to formula (I): | 09-16-2010 |
| 20100222324 | Substituted Indole Compounds - Substituted indole compounds corresponding to the formula I: | 09-02-2010 |
| 20100221322 | Abuse-Resistant Pharmaceutical Dosage Form - A solid pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that could be subject to abuse and at least one antagonist for the active substance, which antagonist is spatially separate from the active substance. The active substance or substances is/are present in at least one subunit (a), and the at least one antagonist is present in at least one subunit (b), and the at least one antagonist in subunit (b) is to all intents and purposes not released in the body if the dosage form is correctly administered as prescribed. | 09-02-2010 |
| 20100196473 | Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release - Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro release rate: 3-35 wt. % (relative to 100 wt. % of active ingredient) of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol released after 0.5 hours, 5-50 wt. % after 1 hour, 10-75 wt. % after 2 hours, 15-82 wt. % after 3 hours, 30-97 wt. % after 6 hours, more than 50 wt. % after 12 hours, more than 70 wt. % after 18 hours, and more than 80 wt. % after 24 hours. | 08-05-2010 |
| 20100190752 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 07-29-2010 |
| 20100173889 | Substituted Pyrimidine and Triazine Compounds - Substituted pyrimidine and triazine compounds corresponding to formula I | 07-08-2010 |
| 20100160447 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 06-24-2010 |
| 20100152158 | Substituted Disulfonamide Compounds - Substituted disulfonamide compounds corresponding to formula I: | 06-17-2010 |
| 20100113417 | Substituted Spiroamine Compounds - Substituted spiroamine compounds corresponding to the formula (I) | 05-06-2010 |
| 20100105722 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators - Substituted tetrahydrothienopyridines corresponding to formula (1) | 04-29-2010 |
| 20100099916 | Process for the Preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol - The present invention relates to a process for the preparation of (1R,2R)- | 04-22-2010 |
| 20100098758 | Abuse-Resistant Dosage Form - A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed. | 04-22-2010 |
| 20100076085 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl-(cyclohex-1-yl))phenol - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 03-25-2010 |
| 20100069501 | Pharmaceutical Composition Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and Paracetamol - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-18-2010 |
| 20100068290 | COATED PELLETS - Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and
| 03-18-2010 |
| 20100063148 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-11-2010 |
| 20100063009 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1.3-diol and an NSAID - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one non-steroidal anti-inflammatory drug (NSAID) component; a pharmaceutical composition and a dosage form comprising such as combination, and a method of treating pain and/or ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, in which component (a) may be administered before or after component (b), and in which components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-11-2010 |
| 20100048554 | Spirocyclic Cyclohexane Compounds - Spirocyclic cyclohexane compounds corresponding to formula I | 02-25-2010 |
| 20100048553 | Spirocyclic Cyclohexane Compounds - Spirocyclic cyclohexane compounds corresponding to formula I | 02-25-2010 |
| 20100004341 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for Therapy of Fibromyalgia - Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof suitable for treating fibromyalgia or chronic pain due to fibromyalgia, and related methods of treating fibromyalgia or chronic pain due to fibromyalgia are described. | 01-07-2010 |
| 20100004252 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN - Substituted tetrahydropyrrolopyrazine compounds corresponding to the formula I: | 01-07-2010 |
| 20090326271 | Preparation of 3-[(1R,2R)-3-(Dimethylamino)-1Ethyl-2-Methylpropyl]phenol - The present invention relates to an improved process for the preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride. | 12-31-2009 |
| 20090298812 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to the formula I | 12-03-2009 |
| 20090286833 | Substituted Cyclohexylmethyl Compounds - Novel cyclohexylmethyl compounds corresponding to formula I | 11-19-2009 |
| 20090286831 | VR1 Receptor Ligands and u-Opioid Receptor Ligands for the Treatment of Pain - A pharmaceutical composition comprising i) at least one composition that has affinity to the μ-opioid receptor, and at least one compound that has affinity to the VR1 receptor, or ii) at least one compound, in particular at least one compound corresponding to formula (I), (II), (III), (IV) or (V), that has affinity to the μ-opioid receptor and to the VR1 receptor, and also to the use of the pharmaceutical compositions i) and ii) for the production of a drug for the treatment of pain. | 11-19-2009 |
| 20090275628 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments - The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments. | 11-05-2009 |
| 20090275558 | SUBSTITUTED SULFONAMIDE COMPOUNDS - Substituted sulfonamide compounds corresponding to formula I | 11-05-2009 |
| 20090264407 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to formula I: | 10-22-2009 |
| 20090264400 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to formula I: | 10-22-2009 |
| 20090258880 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions - Substituted tetrahydropyrrolopyrazine compounds corresponding to formula I | 10-15-2009 |
| 20090253936 | Process for Producing (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-d- iol - A process for producing (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or mixtures thereof. | 10-08-2009 |
| 20090253669 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to the formula I: | 10-08-2009 |
| 20090215858 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs - The invention relates to substituted benzo-condensed cycloheptanone derivatives, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs. | 08-27-2009 |
| 20090215758 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs - The invention relates to 2,5-disubstituted thiazol-4-one derivatives and to their use in the production of drugs, to methods for producing them and to drugs containing said compounds. | 08-27-2009 |
| 20090203672 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to the formula I′ | 08-13-2009 |
| 20090197960 | Method of Inhibiting Polyneuropathic Pain with 3-(2-Dimethylaminomethylcyclohexyl) Phenol - A method of using 3-(2-dimethylaminomethylcyclohexyl)phenol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient for treating or inhibiting polyneuropathic pain, in particular in diabetic polyneuropathy. | 08-06-2009 |
| 20090186947 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 07-23-2009 |
| 20090186902 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions - Substituted tetrahydroimidazopyridine compounds corresponding to formula I: | 07-23-2009 |
| 20090186899 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to the formula I | 07-23-2009 |
| 20090176811 | Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds - Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds, corresponding to formula I | 07-09-2009 |
| 20090156590 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 06-18-2009 |
| 20090149534 | Crystalline modifications of (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol - Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, pharmaceutical compositions which contain these modifications, and the use thereof to treat pain or other conditions. | 06-11-2009 |
| 20090137573 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments - 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides corresponding to formula I | 05-28-2009 |
| 20090136989 | Method of Measuring the Activity of G(alpha)i-or G(alpha)o-Coupled Receptors Using Ca2+ Influx in Cells - A method of measuring the activation or deactivation of G(alpha)i- or G(alpha)o-coupled receptors, and methods of identifying agonists or antagonists of such receptors. | 05-28-2009 |
| 20090111842 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY - Spirocyclic cyclohexane compounds corresponding to formula I | 04-30-2009 |
| 20090105290 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs - The present invention relates to substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one compounds, to methods for the production thereof, to medicaments containing these compounds and to the use of these compounds for producing medicaments. | 04-23-2009 |
| 20090099138 | PHARMACEUTICAL COMBINATION - A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 04-16-2009 |
| 20090076086 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF - Substituted nicotinamide compounds corresponding to formula I | 03-19-2009 |
| 20090076001 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments - The present invention relates to substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compound corresponding to formula I, methods for producing them, to medicaments containing these compounds, the use of these compounds for producing medicaments and related treatment methods | 03-19-2009 |
| 20090069330 | Substituted Oxazole Compounds with Analgesic Activity - Substituted oxazole derivatives corresponding to formula 1: | 03-12-2009 |
| 20090069320 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof - Substituted 4-amino-quinazoline compounds corresponding to formula I | 03-12-2009 |
| 20090062383 | Salts of Substituted Allophanates and Their Use in Drugs - The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments. | 03-05-2009 |
| 20090048323 | SUBSTITUTED IMIDAZOLINE COMPOUNDS - Substituted imidazoline derivatives corresponding to Formula I: | 02-19-2009 |
| 20090043132 | Process for Preparing a Substituted Dimethyl-(3-arylbutyl)amine Compound by Homogeneous Catalysis - Compounds of the formula II | 02-12-2009 |
| 20090042945 | Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands - The present invention relates to substituted benzo[d]isoxazol-3-yl-amine compounds, methods for their production, medicaments containing these compounds and the use of these compounds to produce medicaments. | 02-12-2009 |
| 20090012180 | Titration of Tapentadol - The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a| 01-08-2009 | |
| 20090005458 | Tapentadol for Treating Pain due to Osteoarthritis - The use of tapentadol for treating pain due to osteoarthritis. | 01-01-2009 |
| 20090005427 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS - Substituted oxadiazole compounds corresponding to formula I: | 01-01-2009 |
| 20090005399 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof - Substituted imidazo[2,1-b]thiazole compounds corresponding to formula I, | 01-01-2009 |
| 20090004267 | Dosage Form with Impeded Abuse - A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm. | 01-01-2009 |
| 20080312301 | Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof - The invention relates to substituted N-benzo[d]isoxazol-3-yl-amine derivatives of formula (I) wherein R | 12-18-2008 |
| 20080312268 | Substituted tricyclic piperidone compounds - Substituted tricyclic piperidone derivatives corresponding to Formula I: | 12-18-2008 |
| 20080312231 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds corresponding to formula I | 12-18-2008 |
| 20080306161 | Use of Axomadol for Treatment of Arthrosis Pain - The use of axomadol for the treatment of pain in arthrosis. | 12-11-2008 |
| 20080306084 | Substituted Amide Compounds - Substituted amide compounds corresponding to formula I: | 12-11-2008 |
| 20080300569 | Storage-Stable Oral Dosage Form of Amoxicillin and Clavulanic Acid - An airtight-packaged system including:
| 12-04-2008 |
| 20080300256 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs - Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds corresponding to formula I, methods for the preparation thereof, pharmaceutical compositions containing said compounds, the use of said compounds for preparing pharmaceutical compositions and related treatment methods. | 12-04-2008 |
| 20080293749 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position - Pyrrolidine(thi)one compounds substituted by heterocyclic substituents in the 3-position, their preparation and use in pharmaceutical compositions, in particular as immunomodulators for treatment and/or inhibition of inflammatory and autoimmune diseases and haematological-oncological diseases. | 11-27-2008 |
| 20080275044 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions - Compounds corresponding to formula I: | 11-06-2008 |
| 20080274146 | Application System for a Plaster Containing an Active Ingredient and a Controlled-Release Agent for Said Active Ingredient - The present invention relates to an application system for an active ingredient release system, comprising a film-form application strip, which is in each case bonded detachably to an active ingredient-containing plaster and a separate active ingredient release regulator separate there from. | 11-06-2008 |
| 20080269524 | Separation of Stereoisomeric N,N-Dialkylamino-2Alkyl-3-Hydroxy-3-Phenylalkanes - The invention concerns a method for the isolation of a stereoisomer from a mixture comprising the two stereoisomers of the general formulae (I-A) and (I-A′) and/or the two stereoisomers of the general formulae (I-B) and (I-B′) | 10-30-2008 |
| 20080269326 | Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain - Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy. | 10-30-2008 |
| 20080269289 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions - Compounds corresponding to formula I: | 10-30-2008 |
| 20080269271 | Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments - The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments. | 10-30-2008 |
| 20080262039 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 10-23-2008 |
| 20080261934 | Dosage Form for Hormonal Contraception - A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 μg of folic acid and the daily units B contain >200 μg up to the maximum permissible amount of folic acid for women. | 10-23-2008 |
| 20080255242 | HCI POLYMORPHS OF 3-((2-(DIMETHYLAMINO)METHYL(CYCLOHEX-1-YL)) PHENOL - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)] phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 10-16-2008 |
| 20080249128 | Substituted Sulfonamide Compounds - Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states. | 10-09-2008 |
| 20080249035 | Polymorph of Clarithromycin (Form V) - A polymorphic form of clarithromycin (form V) which exhibits a characteristic X-ray diffraction pattern, a method for producing such polymorphic clarithromycin, and the use of such polymorphic clarithromycin to treat bacterial infections. | 10-09-2008 |
| 20080227819 | Method for identifying the agonistic activity of a target compound on a potassium channel - A method for identifying the agonistic activity of a target compound on a potassium channel by a) providing a population of cells expressing a potassium channel and, optionally providing, a protein-based fluorescent-optical voltage sensor, b) if necessary, incubating the cells with a voltage-sensitive fluorescent dye, c) adding the target compound to the reaction batch of a) or b), d) determining a value F | 09-18-2008 |
| 20080221141 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency. | 09-11-2008 |
| 20080214807 | Substituted Spiro Compounds and their Use for Producing Drugs - The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments. | 09-04-2008 |
| 20080213358 | Method And Device For Ultrasound-Pressing A Tablet Or A Multiparticulate Medicament - The present invention relates to a method and a device for shaping a pharmaceutically active substance in the form of powders, granules, multiparticulate medicaments, in particular pellets and microcapsules, for the production of a tablet or a multiparticulate medicament by means of ultrasound, with an ultrasound generator, a sonotrode and a mould, into which the pharmaceutically active substance can be poured. | 09-04-2008 |
